More than 60,000 new cases of bladder cancer are diagnosed each year in the US
accounting for approximately 13,000 deaths annually. 1 When initially diagnosed, most …

Bladder carcinoma is the most common malignancy of the urinary tract. Approximately 75–
85% of patients with bladder cancer present with a disease that is confined to the mucosa …

Purpose: We determine if intravesical bacillus Calmette-Guerin (BCG) reduces the risk of
progression after transurethral resection to stage T2 disease or higher in patients with …

Purpose: We compare the therapeutic efficacy and toxicity of intravesical bacillus Calmette-
Guerin (BCG) with mitomycin C on recurrence of stages Ta and T1 bladder carcinoma …

Objectives: After transurethral resection, the local and systemic side effects of Bacillus
Calmette-Guerin (BCG) instillations were assessed during a 6-week induction course …

Simple Summary Bacillus Calmette–Guérin (BCG), a live attenuated strain of Mycobacterium
bovis, is the most successful microbial immunotherapy of cancer in current use. Intravesical …

What's known on the subject? and What does the study add? The standard treatment for non‐
muscle invasive bladder (NMIBC) is transurethral resection followed by intravesical therapy …

Abstract Purpose of Review The treatment options for high-risk non-muscle invasive bladder
cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising …

Accumulating evidence suggests the idea that chronic inflammation may play a critical role
in various malignancies including bladder cancer and long-term treatment with non-steroidal …

Bladder cancer is the most common tumor of the urinary system, with a high incidence in the
male population. Surgery and intravesical instillations can eradicate it, although recurrences …